Compare iShares MSCI Indonesia ETF (EIDO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Gilead Sciences, Inc. — how do they compare? iShares MSCI Indonesia ETF trades at $12.68, while Gilead Sciences, Inc. trades at $136.86 (market cap $168.35B). The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while iShares MSCI Indonesia ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | GILD | |
|---|---|---|
52-Week High | $19.22 | $155.80 |
52-Week Low | $10.80 | $110.56 |
Market Cap | — | $168.35B |
Sector | — | Health |
Enterprise Value | — | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $12.64, down 0.86% on the day, with a bearish technical signal from moving averages and mixed oscillators. The stock faces headwinds from foreign capital outflows in Asian equities and Indonesia's economic exposure. A dividend of $0.23 is scheduled for payment in June 2026, offering income potential amid weak price action.
The outlook remains cautious due to technical downtrends and macroeconomic pressures on Indonesian assets. Investment appeal hinges on valuation discounts and potential policy support, but risks include currency volatility and limited earnings growth. Investors require patience for a turnaround.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
